IL5 and type 2 diabetes mellitus: Intraperitoneal injection of ES products resulted in reduced glucose levels and reduced body weight gain in a mouse model of T2D, and was accompanied by activation of eosinophilia and elevated IL-5, as well as a shift in the microbiota profile between the groups treated with ES products compared with untreated littermates fed both normal chow and high glycaemic index diets.